trial

Oxytocin Add on Study for Stable Schizophrenic Patients

NCTId NCT00506909
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 21 (actual)
Sponsored by David Feifel
Primary completion 2014-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2008-03
Primary completion
2014-03
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

David FeifelLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
David Feifel, MD, PhDPrincipal Investigator

Sites

1 total
San Diego, United States

Facts & assertions

4 sourced
Enrollment
21
Phase
NA
Primary Completion Date
2014-03
Status
TERMINATED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
David Feifel
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David Feifel, MD, PhD
person